BIVI Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 22:00):

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States...

Stats
Dagens volum	312 670
Gjennomsnittsvolum	2.59M
Markedsverdi	26.63M
EPS	$0 ( 2024-02-09 )
Neste inntjeningsdato	( $-0.330 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.410
ATR14	$0.00300 (0.62%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-04	Do Cuong V	Buy	10 000	Common stock
2024-03-04	Do Cuong V	Buy	5 000	Warrants (right to buy)
2023-12-11	Kim Joanne Wendy	Buy	5 000	Common Stock
2023-11-09	Lang James Paul	Buy	93 500	Stock Option (right to buy)
2023-11-09	Gorlin Steve	Buy	46 358	Common Stock

INSIDER POWER
91.52
Last 94 transactions
Buy: 39 235 676 \| Sell: 4 917 434

Volum Korrelasjon

Lang: -0.03 (neutral)

Kort: -0.22 (neutral)

Signal:(48.226) Neutral

Biovie Inc Korrelasjon

10 Mest positive korrelasjoner
IONM	0.843
CIDM	0.823
AACG	0.818
GAINL	0.807
CERC	0.806
AMRB	0.802

10 Mest negative korrelasjoner
DBX	-0.895
RMRM	-0.894
PCT	-0.882
PTC	-0.866
NOVT	-0.864
OPEN	-0.861
CVAC	-0.846
XP	-0.845
FTHM	-0.842
EXPI	-0.842

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Biovie Inc Korrelasjon - Valuta/Råvare

0.00
( neutral )

-0.01
( neutral )

Biovie Inc Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-266 842 (0.00 %)
EPS:	$-1.550

FY	2023
Omsetning:	$0
Bruttogevinst:	$-266 842 (0.00 %)
EPS:	$-1.550

FY	2022
Omsetning:	$0
Bruttogevinst:	$-237 421 (0.00 %)
EPS:	$-0.920

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-10.50

Financial Reports:

No articles found.

Biovie Inc

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.